Skip to main content
Equibles

GSA CAPITAL PARTNERS LLP

Position in DSGN — Design Therapeutics, Inc.

CIK 1362033 LONDON, X0
Back to DSGN Full portfolio

Position in DSGN

as of Jun 30, 2026 · filed Aug 6, 2026
Position Value
$149,446
-$52,669 QoQ
Shares Held
10,328
-82.8% QoQ
Ownership
0.017%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#94
of 136 holders
Holding Since
Dec 2022
12 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in DSGN Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Jun 30, 2026

GSA CAPITAL PARTNERS LLP holds $104,909,103 across 164 Biotechnology names. DSGN ranks #135 (0.1% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 IOVA
Iovance Biotherapeutics, Inc.
 655,318 $2,726,122
2 IMVT
Immunovant, Inc.
 65,267 $2,514,737
3 GOSS
Gossamer Bio, Inc.
 187,337 $2,472,846
4 AXSM
Axsome Therapeutics, Inc.
 9,419 $2,305,488
5 CABA
Cabaletta Bio, Inc.
 668,563 $2,079,230
6 MLTX
MoonLake Immunotherapeutics
 106,695 $2,077,351
7 ATYR
aTYR PHARMA INC
 3,454,863 $2,062,553
8 CORT
Corcept Therapeutics Inc
 23,257 $2,022,196

All Filings in DSGN

Export CSV
12 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $149,446 10,328
2025-06-30 $202,115 59,975
2025-03-31 $278,495 72,149
2024-12-31 $730,083 118,328
2024-09-30 $934,742 173,744
2024-06-30 $703,342 209,953
2024-03-31 $871,878 216,347
2023-12-31 $191,573 72,292
2023-09-30 $102,851 43,581
2023-06-30 $1,500,660 238,200
2023-03-31 $564,883 97,900
2022-12-31 $139,730 13,619